
Diabetes, hypertension, and prehypertension could increase the risk of dementia regardless of race.
Diabetes, hypertension, and prehypertension could increase the risk of dementia regardless of race.
The National Standards for Diabetes Self-Management Education and Support (DSMES) have been updated for the first time in 3 years to reflect the latest recommended standards for diabetes care.
Findings highlight the need for interventions that target obesity in adults aged 18 to 34.
The American Diabetes Association and the American Association of Diabetes Educators report seeks to improve self-care and management of the chronic condition.
Glycemic control may reduce cardiovascular disease-related mortality among older patients with type 1 diabetes.
Legislation seeks to fight drug cost increases by creating transparency in the pricing activities of manufacturers and pharmacy benefit managers.
Boehringer Ingelheim and Eli Lilly partner with ACC to highlight the role of cardiologists in heart health among diabetes patients.
Is it time to change the type 2 diabetes treatment paradigm?
Severe diabetic retinopathy has a more detrimental effect on visual function than lesser forms of the disease.
Diabetes is associated with a greater risk of developing cardiovascular disease (CVD), especially when the disease is not well controlled.
Galantamine observed to reduce pro-inflammatory markers in patients with metabolic syndrome.
Gaining more than 5 pounds linked to several chronic diseases and overall poor health.
Inhibiting beta cell infection from enteroviruses may prevent the development of type 1 diabetes.
Some diabetes drugs may impact bone metabolism and strength.
The National Diabetes Statistics Report found that 1 in 4 patients are unaware they have diabetes.
The FDA has granted tentative approval to Merck's Lusduna Nexvue (insulin glargine injection) 100 units/mL. The drug is a follow-on biologic basal insulin for patients with type 2 diabetes and is administered through a pre-filled dosing device, according to a press release.
Lusduna Nexvue insulin glargine injection is a follow-on biologic for patients with type 2 diabetes.
Sanofi lawsuit delays emergence of follow-on biologic of insulin glargine injection for type 2 diabetes.
This article contains a great snapshot into U-500 education to further your knowledge and promote patient safety.
The National Diabetes Statistics Report, released approximately every 2 years, provides information on diabetes prevalence and incidence, prediabetes, risk factors for complications, acute and long-term complications, mortality, and costs in the United States.
Type 2 diabetes can alter the oral microbiome and lead to inflammation.
Web-based weight loss intervention shows promise addressing obesity in patients with type 2 diabetes.
An asthma drug may potentially be useful in treating type 2 diabetes, according to a recently-published study.
The Alexa Diabetes Challenge harnesses voice-activated technology to improve diabetes outcomes.
Top news of the day from across the health care landscape.